Background Survival after coronary artery bypass graft surgery (CABG) and medical therapy in patients with coronary artery disease (CAD) has been studied in both randomized trials and observational treatment comparisons. Over the past decade, the use of coronary angioplasty (PTCA) has increased dramatically, without guidance from either randomized trials or prospective observational comparisons. The purpose of this study was to describe the survival experience of a large prospective cohort of CAD patients treated with medicine, PTCA, or CABG.
Methods and Results The study was designed as a prospective nonrandomized treatment comparison in the setting of an academic medical center (tertiary care). Subjects were 9263 patients with symptomatic CAD referred for cardiac catheterization (1984 through 1990) . Patients with prior PTCA or CABG, valvular or congenital disease, nonischemic cardiomyopathy, or significant (.75%) left main disease were excluded.
Baseline clinical, laboratory, and catheterization data were collected prospectively in the Duke Cardiovascular Disease Databank. All patients were contacted at 6 months, 1 year, and annually thereafter (follow-up 97% complete). Cardiovascular death was the primary end point. Of this cohort, 2788 patients were treated with PTCA (2626 within 60 days) and 3422 with CABG (3080 within 60 days). Repeat or crossover revascularization procedures were counted as part of the initial treatment strategy. Kaplan-Meier survival curves (both unadjusted and adjusted for all known imbalances in baseline prognostic factors) were used to examine absolute survival differences, and treatment pair hazard ratios from the Cox model were used to summarize average relative survival benefits. For the latter, a 13-level CAD prognostic index was used to examine the relation between survival and revascularization as a function of CAD severity. The effects of revascularization on survival depended on the extent of CAD. For the least severe forms of CAD (ie, one-vessel disease), there were no survival advantages out to 5 years for revascularization over medical therapy. For intermediate levels of CAD (ie, two-vessel disease), revascularization was associated with higher survival rates than medical therapy. For less severe forms of two-vessel disease, PTCA had a small advantage over CABG, whereas for the most severe form of two-vessel disease (with a critical lesion of the proximal left anterior descending artery), CABG was superior. For the most severe forms of CAD (ie, threevessel disease), CABG provided a consistent survival advantage over medicine. PTCA appeared prognostically equivalent to medicine in these patients, but the number of PTCA patients in this subgroup was low.
Conclusions In this first large-scale, prospective observational treatment comparison of PTCA, CABG, and medicine, we confirmed the previously reported survival advantages for CABG over medical therapy for three-vessel disease and severe two-vessel disease. For less severe CAD, the primary treatment choices are between medicine and PTCA. In these patients, there is a trend for a relative survival advantage with PTCA, although absolute survival differences were modest. In this setting, treatment decisions should be based not only on survival differences but also on symptom relief, quality of life outcomes, and patient preferences. (Circulation. 1994; 89:2015 -2025 physician.
Follow-up Procedures
Patients were contacted at 6 months and 1 year after presentation and then annually. Importantly, our conclusions were unchanged when all-cause mortality was substituted as the end point for analysis.
Data Analysis Descriptive Stasics
Baseline characteristics were summarized with medians and interquartile ranges for continuous variables and percentages for discrete variables. For the purposes of describing baseline characteristics (Tables 3 and 4 patients were initially considered to be medically treated.
When patients underwent their initial revascularization procedure, their medical follow-up was censored and their follow-up was restarted at time zero in the appropriate revascularization group (Fig 1) . This method of assigning treatment is identical to that used in our previous observational treatment comparison of medicine and CABG4 and is also the same as "method A" used by the CASS group in their nonrandomized 
Statistical Testing and Treatment Comparisons
Treatment comparisons are presented in this paper in two main formats: Kaplan-Meier survival curves (unadjusted and adjusted) to contrast absolute survival differences and hazard ratios from the Cox model to compare relative survival differences of the three treatments (taken two at a time) according to levels of the Duke prognostic CAD index (Table 2) . Because the hazard ratios involve a direct treatment comparison, the calculations required refitting Cox models in which the treatment group was used as a covariate rather than as a stratification factor. Since early procedural mortality creates a pattern of crossing survival curves, the proportional-hazards assumptions of the Cox model are violated. The typical effect of this violation is to make statistical treatment comparisons more conservative and confidence limits on the hazard ratios wider.
Hazard ratios are presented with 99% confidence limits rather than 95% limits because a more conservative position is warranted by the multiple comparisons involved in calculating separate hazard ratios for each level of the CAD index. Confidence limits that do not intersect the 1.0 line of treatment equivalence are indicative of a treatment difference that is significant at the .01 level.
Results
Baseline clinical characteristics are shown in Table 3 for the 2626 patients receiving PTCA as their initial revascularization procedure within 60 days of catheterization, the 3080 patients initially treated with CABG within 60 days, and the 3557 patients who were treated medically for at least 60 days. Although there was much overlap among groups in these clinical characteristics, some trends were evident (Table 3) . Median age was lowest in the PTCA group and highest in the CABG group. CABG patients had more progressive or unstable anginal symptoms, whereas the PTCA group had the highest prevalence of acute myocardial infarction (catheterization within 24 hours of presentation). CABG patients had been symptomatic the greatest period of time, whereas PTCA patients had a median of 1 month between the date of symptom onset and catheterization. The medical patients had the highest prevalence of any congestive heart failure and of class IV heart failure. Major comorbidity, including renal insufficiency, chronic obstructive lung disease, and cancer, was also slightly more prevalent in the medical group.
The biggest differences among groups were found in the distribution of baseline catheterization characteristics (Table 4 ). In particular, 61% of the PTCA group had one-vessel disease and 10% three-vessel disease, whereas for CABG the proportions were essentially reversed (10% and 56%, respectively). Examination of the CAD index provided more details regarding differences in the distribution of coronary disease among the three groups (Table 4) . PTCA (Fig 3) , revascularization with either PTCA or CABG showed a small advantage over medicine emerging at 1 year of follow-up (adjusted 5-year survivals: PTCA, 91%; CABG, 91%; medicine, 86%). In contrast, in the group with three-vessel disease (Fig 4) , which had the smallest number of PTCA patients (n=260), CABG was superior to both medicine and PTCA (adjusted 5-year survivals: CABG, 89%; PTCA, 81%; medicine, 72%).
To ensure that these results were not due to inappropriate combination of survival experience from acute or recent myocardial infarction patients with other symptomatic CAD patients, we generated the same survival curves after excluding patients with a myocardial infarc- (Table  2 ) to calculate Cox model estimated hazard or mortality ratios for pairs of treatments against nine levels of coronary disease severity. Hazard ratios summarize the relative effect of one treatment versus another on mortality averaged over the 5-year follow-up period. Fig  6 shows the hazard ratios for CABG and medical therapy along with 99% confidence limits. In the least severe categories of CAD (left side of Fig 6) , there is a trend favoring medicine, although the confidence limits include the possibility of no effect (ie, hazard ratio of 1) or even benefit from CABG. In the more severe forms of one-vessel disease and the less severe forms of two-vessel disease, the two therapies appear equivalent, whereas in severe two-vessel disease (with a 95% proximal LAD lesion) and all forms of three-vessel disease, CABG clearly improves survival relative to medicine by 36% to 63%.
A similar comparison is shown in Fig 7 for medical therapy and PTCA. In one-vessel disease categories and the less severe forms of two-vessel disease, there is a trend for PTCA to reduce mortality relative to medicine by approximately 20%, although in every case the confidence limits cross the 1.0 hazard ratio line of identity. In severe two-vessel disease (with 95% proximal LAD involvement) and all forms of three-vessel disease, the estimated benefit of PTCA is 10% to 15% and the confidence limits suggest an equivalent effect on survival.
The final set of hazard ratios involving CABG and PTCA is shown in Fig 8. In the less severe forms of oneand two-vessel disease, PTCA reduced mortality by almost 50% relative to CABG. In severe one-vessel disease (with 95% proximal LAD involvement) and moderate two-vessel disease, the two therapies had an equivalent effect on survival, whereas in severe twovessel disease (with 95% proximal LAD involvement) and all forms of three-vessel disease, there was a clear survival benefit for CABG, with the magnitude of the benefit (25% to 60% mortality reduction) proportional to the severity of the coronary disease.
Discussion
This study is the first large-scale prospective observational treatment comparison of 5-year survival outcomes with PTCA, CABG, and medical therapy. The major findings are as follows. First, we confirmed the survival benefits of CABG relative to medicine that had been reported for CAD patients treated during the 3 Vessel Disease (Fig  6) . Furthermore, the magnitude of survival benefits was clearly a function of the severity of the CAD present, with more severe CAD associated with greater benefit.4,U Second, in less severe forms of CAD, PTCA showed a modest survival advantage over CABG (Fig  8) . In the most severe category of one-vessel disease and moderate two-vessel disease (both involving LAD lesions), however, PTCA and CABG appeared prognostically equivalent, whereas in the most severe forms of CAD, PTCA had prognostic effects equivalent to medicine (Fig 4) . Finally, comparing PTCA and medicine (Fig 7) , there was a definite trend favoring PTCA in the less severe forms of CAD, although this did not reach statistical significance. Starting with severe two-vessel disease and continuing with all forms of three-vessel disease, PTCA and medicine appeared prognostically equivalent. Typically, when survival differences between treatment alternatives are present, they are largest in absolute terms in high-risk patients and smallest in low-risk patients. 4 In the case of low-risk patients, such as those with one-vessel disease, the small absolute differences present in the survival outcomes of alternative therapies may be of less consequence in decision making than effects on symptom status or patient preferences, whereas in high-risk patients, survival considerations may dominate. Although our results by themselves are not sufficient for individual patient treatment selection (since they do not include either symptom status or patient preferences), they do provide a conceptual framework for such decisions. Generally, medicine or PTCA should be the preferred initial strategies for low-risk CAD (eg, one-vessel disease), whereas CABG should be preferred in many high-risk CAD patients (eg, three-vessel disease). In the intermediate levels of CAD severity, revascularization offers a modest survival advantage by 5 years relative to medicine, with CABG offering an advantage for the highest-risk patients of the group (ie, those with a critical proximal LAD lesion) and PTCA preferable for many of the remainder.
To date, only one randomized trial has compared outcomes between PTCA and medical therapy for patients with angina. 10 The ACME trial, involving 212 patients with single-vessel disease, reported better 6-month symptom and functional status after PTCA. However, the study was not intended to be large enough to evaluate mortality outcomes. No other randomized comparison of PTCA and medicine is currently under way, although the ACME group is planning a trial in lower-risk multivessel-disease patients. Five randomized trials are being conducted to compare PTCA and CABG, four of which are restricted to multivessel CAD. The largest of these trials, the National Heart, Lung, and Blood Institute (NHLBI) BARI trial, enrolled 1829 patients; the other trials are substantially smaller. Two of these trials, the NHLBI BARI trial12 and the UK RITA trial,29 have "hard event" primary end points of death and myocardial infarction, whereas the other three (EAST, CABRI, and GABI) are smaller and have composite end points that include both cardiac events and other measures such as thallium defects or anginal symptoms. 13 Recently published interim results from the RITA trial reveal no survival differences between PTCA and CABG at a mean follow-up of 2.5 years.11
To date, no prospective nonrandomized treatment comparisons of long-term survival with medicine versus PTCA have been reported. A nonrandomized treatment comparison from Emory of PTCA and CABG in patients with two-vessel disease reported identical adjusted 5-year survival results for PTCA and CABG at 93%.3°Our study had very similar results, with adjusted 5-year survival rates of 91% for both PTCA and CABG (Fig 3, right) . In our study, there was heterogeneity in the relative effects of PTCA and CABG on different subtypes of two-vessel disease (Fig 8) . This possibility was not examined in the Emory study. Recently, investigators from the Cleveland Clinic conducted a 588-patient matched-pair comparison of PTCA and CABG for multivessel CAD using the patient selection criteria Our analysis strategy of starting all CABG and PTCA patients in the medical therapy group and then restarting them at time zero in the appropriate revascularization group with updated baseline covariates is one of several ways that have been used to control waiting-time bias in observational treatment comparisons. We have also performed our treatment comparisons using arbitrary time windows (eg, 60 days, 90 days). To correct for waiting-time bias using this approach, which was used by the CASS group as "method B." we started medical follow-up at the average value of the time from catheterization to revascularization (7 days for PTCA and 14 days for CABG in our population).23 This approach yielded results that are virtually the same as those presented. Thus, we do not feel that the choice of analytical methods used in our study affects our final results.
In this study, we have presented only data on cardiovascular mortality end points. Additional analyses (not presented) have shown similar results for all-cause mortality. As noted above, repeat procedures and crossovers between PTCA and CABG and their consequences have been analyzed as part of the initial treatment strategy (Fig 1) . We going PTCA and is actually achieved in only two thirds of the patients in whom it is attempted (ie, 25% to 50% of two-vessel disease and 9% to 25% of three-vessel disease patients).36-38 One of the main reasons for these low figures appears to be chronic total occlusions, which are associated with lower PTCA success rates and relatively high complication rates. 36, 38 Another potential reason is the substantial increase in the number of angiographically identifiable individual lesions that are present in more severe CAD patients that must be attempted so as to provide complete revascularization. Each site of dilation represents another opportunity for abrupt closure or other acute complications and for eventual restenosis. Consequently, the vast majority of PTCA patients currently being treated receive three or fewer individual lesion dilations.39A40
There are several important limitations that must be considered in the interpretation of this study. First, despite extensive efforts to control for treatment selection bias by use of both standard covariate adjustments and covariate adjustment with treatment propensity scores, we cannot rule out the possibility that residual selection bias accounts for some of our observed treatment differences. Covariate adjustment can only correct for observed imbalances. Unobserved or unmeasured factors affecting both treatment selection and outcome could have influenced our results. The consistency of our CABG/medicine results with those reported previously by US4 and others provides at least a measure of reassurance against this concern. However, this success of a previous observational treatment comparison does not guarantee the accuracy of the present analysis, and direct validation of our results against the larger PTCA/ CABG randomized trials will not be possible for several more years.
Second, the effects of lesion morphology on outcome are not considered in our analysis. There is no evidence that lesion-specific details, such as are contained in the American Heart Association/American College of Cardiology classification, affect outcome with medicine or CABG, but the long-term prognostic effects in the PTCA population are uncertain. Certainly, the relation between specific morphological characteristics and acute success and complication rates have been well described. 41, 42 However, unless such factors are strongly associated with subsequent mortality, no long-term prognostic effects may be evident. In a preliminary analysis of this issue, we found no relation between lesion morphology and long-term survival in our PTCA cohort,43 so we do not feel that variations in lesionspecific characteristics in the PTCA cohort affected our results.
Finally, treatment selection in CAD is a complex decision involving consideration of multiple dimensions of outcome, including functional status, symptom relief, and perceived quality of life. Data on survival effects of therapy, whether from observational studies or randomized trials, can only be one part of this decision and must be interpreted in light of those other dimensions. In particular, among low-risk patients with coronary disease, consideration of likely functional status and quality of life outcomes should carry particular weight and are currently being analyzed in our patient population. Ultimately, such multidimensional outcome data will need to be combined with subjective patient preference data to define not only the benefits of different treatment options but also whether they are worthwhile. 44 
